Curium Said to Near $7 Billion Acquisition of Lantheus Holdings in Radiopharma Consolidation Play

The Quick Take

• Curium is in advanced talks to acquire Lantheus Holdings (LNTH) for approximately $7 billion, per Bloomberg sources
• An announcement could come within days as talks reach their final stage
• The deal would consolidate two major radiopharmaceutical players as the sector sees rising clinical and commercial demand

Curium, a privately held European radiopharmaceutical manufacturer, is nearing a roughly $7 billion acquisition of Lantheus Holdings (LNTH), according to Bloomberg, with an announcement potentially imminent. Lantheus is a publicly traded radiopharma company known for its PYLARIFY PET imaging agent, used in prostate cancer detection, and its broader pipeline in diagnostic radiopharmaceuticals. The deal would represent one of the largest transactions in the emerging radiopharmaceuticals space, which has attracted significant pharma industry attention following Eli Lilly's Novartis-inspired investments in radioligand therapies and targeted alpha therapies.

A Curium acquisition of Lantheus would create a scaled radiopharma platform spanning both diagnostics and therapeutics — a combination with strategic advantages in isotope supply chains, hospital distribution networks, and clinical partnerships. For sector peers including RayzeBio (acquired by Bristol-Myers Squibb), NovaBay Pharmaceuticals, and Point Biopharma, the deal reinforces radiopharma as a high-conviction M&A target segment. Lantheus shareholders face an immediate decision framework: a $7 billion valuation implies a premium over recent trading levels, but any competing bid from a strategic pharma player with deeper pockets could emerge before signing.

The critical forward signals include confirmation of deal terms and regulatory filing timelines — radiopharmaceutical acquisitions face NRC (Nuclear Regulatory Commission) review in addition to standard antitrust scrutiny. Pipeline milestones for LNTH's therapeutic candidates (particularly PYLARIFY's reimbursement expansion) will determine how the $7 billion valuation holds under due diligence. The macro variable: the FDA's accelerating approval pathway for radiopharmaceuticals and Medicare reimbursement policy for novel imaging agents will determine the long-run revenue ceiling for any combined Curium-Lantheus entity.

Synthesized from 1 source.